Pharmafile Logo

UniQure

- PMLiVE

NICE turns down bluebird bio’s gene therapy Zynteglo

Draft guidance does not recommend routine NHS funding for beta thalassaemia treatment

- PMLiVE

FDA approves new indication for Adamas’ Gocovri in Parkinson’s disease

Gocovri approved to treat patients with Parkinson’s disease experiencing OFF episodes

- PMLiVE

After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age

- PMLiVE

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Acquisition includes a number of candidates for neurodegenerative diseases

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

UCB boosts gene therapy offering with a pair of new deals

Company will collaborate with Lacerta Therapeutics and acquire Handl Therapeutics

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

Will offer treatment via an outcomes-based payment model

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

- PMLiVE

Astellas makes gene therapy a core focus with $3bn Audentes buy

Deal includes a late-stage candidate for a rare disease

- PMLiVE

Private equity firm backs Ferring gene therapy venture

Joint venture will focus on development of therapies for bladder cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links